Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin

Rui Sasaki, Taku Fujimura, Chunbing Lyu, Setsuya Aiba

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Enfortumab vedotin (EV) is a novel, fully humanized monoclonal antibody–drug conjugate composed of an anti-Nectin-4 antibody joined to monomethyl auristatin E. In this report, we described a case of a severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing in patients with metastatic urothelial cancer treated with EV. Because phase II and phase III clinical studies are ongoing, in the future, substantial amounts of EV are expected to be used for the treatment of metastatic urothelial cancer. Therefore, understanding the mechanisms of drug eruption caused by EV is important for oncologists as well as dermatologists.

Original languageEnglish
Pages (from-to)1436-1438
Number of pages3
JournalJournal of Dermatology
Volume47
Issue number12
DOIs
Publication statusPublished - 2020 Dec
Externally publishedYes

Keywords

  • enfortumab vedotin
  • full-thickness epidermal necrosis
  • molecular-targeted therapy
  • severe drug eruption
  • tumor-infiltrating leukocytes

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin'. Together they form a unique fingerprint.

Cite this